NPPB and heart failure: All five patients treated with Dex successfully completed chemotherapy as planned, with mean LVEF decreasing from 39% at baseline to 34% after chemotherapy, without symptomatic heart failure or elevated biomarkers (cardiac troponin I or brain natriuretic peptide).